Cambridge Biomedical Campus and Cambridge University Hospitals NHS Trust have aspirations to ‘create a vibrant and ground-breaking health care community at the forefront of science and medicine’. This proposal, which lies on the biomedical campus’ phase 2 development plot, seeks to deliver a research and education facility with clinical trial facilities that accommodate the following two studies. This includes acute/post-surgical, neuropathic, and cancer-related pain and how Hemp and psychedelics can create a better quality of life and pain relief for patients struggling with fatigue, depression, insomnia, and weight loss.

The facilities within the innovation centre include investigating the brain effects of LSD and Hemp, using modern brain imaging sensory and clinical trial rooms. It also includes research laboratories focused on the medical benefits of cannabinoid and psychedelic extraction and education facilities including small-scale seminars and lecture rooms.

The COVID-19 pandemic has disrupted critical mental health services in 93% of countries worldwide while the demand for mental health is increasing, according to a new WHO survey. As well as mental health services, most cancer treatments have also taken a toll from the pandemic, with an urgent need for additional funding and improved treatments. Therefore, the University of Cambridge has set a comprehensive brief to create a research and education facility that has a focus on the end-user satisfaction and wellbeing